NO20016115D0 - Substituerte heterocykelkondenserte gamma-karboliner - Google Patents

Substituerte heterocykelkondenserte gamma-karboliner

Info

Publication number
NO20016115D0
NO20016115D0 NO20016115A NO20016115A NO20016115D0 NO 20016115 D0 NO20016115 D0 NO 20016115D0 NO 20016115 A NO20016115 A NO 20016115A NO 20016115 A NO20016115 A NO 20016115A NO 20016115 D0 NO20016115 D0 NO 20016115D0
Authority
NO
Norway
Prior art keywords
carbolines
substituted heterocycle
gamma
condensed
condensed gamma
Prior art date
Application number
NO20016115A
Other languages
English (en)
Other versions
NO20016115L (no
Inventor
Albert J Robichaud
Taekyu Lee
Wei Deng
Ian S Mitchell
Wenting Chen
Christopher D Mcclung
Emilie J B Calvello
David M Zawrotny
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20016115D0 publication Critical patent/NO20016115D0/no
Publication of NO20016115L publication Critical patent/NO20016115L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20016115A 1999-06-15 2001-12-14 Substituerte heterosykelkondenserte gamma-karbolin NO20016115L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13932199P 1999-06-15 1999-06-15
PCT/US2000/016375 WO2000077001A1 (en) 1999-06-15 2000-06-15 Substituted heterocycle fused gamma-carbolines

Publications (2)

Publication Number Publication Date
NO20016115D0 true NO20016115D0 (no) 2001-12-14
NO20016115L NO20016115L (no) 2002-02-12

Family

ID=22486095

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20016128A NO20016128L (no) 1999-06-15 2001-12-14 Substituerte, heterocykliske, fuserte <gamma>-karboliner
NO20016115A NO20016115L (no) 1999-06-15 2001-12-14 Substituerte heterosykelkondenserte gamma-karbolin
NO20016116A NO20016116L (no) 1999-06-15 2001-12-14 Substituerte heterocykelfuserte <gamma>-karboliner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20016128A NO20016128L (no) 1999-06-15 2001-12-14 Substituerte, heterocykliske, fuserte <gamma>-karboliner

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20016116A NO20016116L (no) 1999-06-15 2001-12-14 Substituerte heterocykelfuserte <gamma>-karboliner

Country Status (19)

Country Link
US (7) US6552017B1 (no)
EP (3) EP1192165B1 (no)
JP (3) JP4762465B2 (no)
CN (3) CN1371374A (no)
AR (3) AR024378A1 (no)
AT (3) ATE277928T1 (no)
AU (3) AU5738000A (no)
BR (3) BR0012086A (no)
CA (3) CA2373920A1 (no)
DE (3) DE60014079T2 (no)
ES (3) ES2228549T3 (no)
HK (3) HK1043112A1 (no)
IL (3) IL147109A0 (no)
MX (3) MXPA01012969A (no)
NO (3) NO20016128L (no)
NZ (1) NZ516031A (no)
TR (1) TR200103658T2 (no)
WO (3) WO2000077010A2 (no)
ZA (1) ZA200109735B (no)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
AR024378A1 (es) * 1999-06-15 2002-10-02 Du Pont Pharm Co Gamma-carbolinas fusionadas heterociclicas sustituidas
JP2004509894A (ja) * 2000-09-20 2004-04-02 ファルマシア・アンド・アップジョン・カンパニー 置換アゼピノ［４，５−ｂ］インドリン誘導体
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
CA2428905A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab PIPERAZINYLPYRAZINE COMPOUNDS FOR USE AS ANTAGONISTS OF THE SEROTONIN 5-HT2 RECEPTOR
KR20030070073A (ko) 2000-12-20 2003-08-27 브리스톨-마이어스스퀴브컴파니 세로토닌 효능제 및 길항제로서의 치환된 피리도인돌
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
WO2002098400A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel arylaminopropane analogues and their use for the treatment of glaucoma
CA2447156A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
ATE318821T1 (de) * 2001-06-01 2006-03-15 Alcon Inc Pyranoindazole und ihre verwendung in der glaukombehandlung
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
EP1414826A1 (en) * 2001-08-06 2004-05-06 PHARMACIA &amp; UPJOHN COMPANY Therapeutically useful tetracyclic ligands
AU2002336749A1 (en) 2001-09-21 2003-04-01 Pharmacia And Upjohn Company Tricyclic indole derivatives as 5-ht ligands
EP1436294A1 (en) * 2001-10-18 2004-07-14 PHARMACIA &amp; UPJOHN COMPANY Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
MXPA05002259A (es) * 2002-08-30 2005-07-05 Alcon Inc Compuestos de 5-croman-5-il-etilamina sustituidos y uso para el tratamiento de glaucoma.
EP1581209A4 (en) 2002-12-13 2009-03-11 Alcon Inc NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
ES2364046T3 (es) * 2002-12-19 2011-08-23 Bristol-Myers Squibb Company Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina.
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EA201200555A1 (ru) 2004-03-15 2013-01-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Производные карболина, полезные в ингибировании ангиогенеза
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
CA2570800A1 (en) 2004-06-18 2006-01-26 Wyeth Processes for preparing 6-alkyl-5-arylsulfonyl- dihydrophenanthridines
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
EP1981337B1 (en) * 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
BRPI0907122B8 (pt) 2008-01-11 2021-05-25 Albany Molecular Res Inc compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
SI2262505T1 (sl) 2008-03-12 2015-03-31 Intra-Cellular Therapies, Inc. Substituirana heterociklirano zliti gama-karbolinska trdna snov
WO2009145900A1 (en) * 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
AU2015218433B2 (en) * 2008-05-27 2017-07-27 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
CA2737031A1 (en) * 2008-09-29 2010-04-01 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
JP5663572B2 (ja) 2009-07-14 2015-02-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ｈｔ３受容体モジュレーター、その作製方法、およびその使用
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011044134A1 (en) 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
RU2591194C2 (ru) * 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2012112961A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating hypertension
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9822117B2 (en) * 2013-03-04 2017-11-21 Daya Drug Discoveries, Inc. Pyridoindolobenz[b,d]azepine derivatives and uses thereof
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
DK2968320T3 (da) 2013-03-15 2021-02-01 Intra Cellular Therapies Inc Organiske forbindelser
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3148303C (en) * 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CA2944512C (en) 2014-04-04 2018-04-24 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10646648B2 (en) 2015-04-01 2020-05-12 Becton, Dickinson And Company IV flow management systems and methods
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
PT3407888T (pt) * 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
SI3407889T1 (sl) 2016-03-25 2021-09-30 Intra-Cellular Therapies, Inc. Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
MD3532459T2 (ro) 2016-10-26 2024-06-30 Constellation Pharmaceuticals Inc Inhibitori ai LSD1 și utilizările medicale ale acestora
WO2018106916A1 (en) * 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Deuterated quinoxaline compounds
WO2018126143A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
EP3609501A4 (en) 2017-04-10 2020-08-19 Dr. Reddy's Laboratories Limited AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
JP7223742B2 (ja) * 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN111107847A (zh) * 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
US11655251B2 (en) 2017-11-27 2023-05-23 Egis Gyogyszergyar Zrt. Method for the production of lumateperone and its salts
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
DK3768271T3 (da) 2018-03-23 2026-03-02 Intra Cellular Therapies Inc Organiske forbindelser
IL277504B1 (en) 2018-03-23 2026-02-01 Intra Cellular Therapies Inc Deuterium-converted ((sa10,rb6)-8-(3-(4-fluorophenoxy)propyl 6b, 7, 8, 9, 10, 10a-hexahydro-1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-82(h3)-one compounds, pharmaceutical composition containing them and their uses
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
DK3609891T3 (da) * 2018-06-11 2026-02-23 Intra Cellular Therapies Inc Syntese af substituerede heterocykliske fusionerede gamma-carboliner
AU2019288476A1 (en) 2018-06-21 2021-03-18 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
CN109100437A (zh) * 2018-07-22 2018-12-28 邯郸学院 仲胺类抗抑郁药物的质谱检测方法
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
BR112021004053A2 (pt) 2018-09-07 2021-05-25 Aquestive Therapeutics, Inc. composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
EP3898580A4 (en) 2018-12-17 2022-08-10 Intra-Cellular Therapies, Inc. SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE
EP3898221A4 (en) * 2018-12-17 2022-09-14 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
WO2020132474A1 (en) * 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
CA3125777A1 (en) * 2019-01-23 2020-07-30 Intra-Cellular Therapies, Inc. Substituted fused heterocycle gamma carbolines for the use in the treatment of opiate addiction
JP7770673B2 (ja) 2019-02-27 2025-11-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのアゼピノ－インドール及び他の複素環化合物
WO2020206391A1 (en) * 2019-04-04 2020-10-08 Intra-Cellular Therapies, Inc. Methods of treating neuropathic pain
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
IL292487A (en) 2019-11-01 2022-06-01 Aquestive Therapeutics Inc Compositions of medicinal meters and methods of treatment
CA3159389A1 (en) 2019-11-14 2021-05-20 Aquestive Therapeutics, Inc. Multimodal compositions comprising diazepam and methods of treatment
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
EP4744678A2 (en) 2019-12-19 2026-05-20 Intra Cellular Therapies Inc LUMATEPERONE FOR THE TREATMENT OF SCHIZOPHRENIA
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
KR102894755B1 (ko) * 2020-10-09 2025-12-02 슈징 바이오파마 컴퍼니 리미티드 헤테로사이클로로 치환된 융합 γ-카르볼린 유도체, 이의 제조 방법, 중간체 및 용도
CN112062767B (zh) * 2020-10-20 2022-03-11 杭州科巢生物科技有限公司 一种卢美哌隆的制备方法及其中间体
WO2022155544A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
CA3210706A1 (en) 2021-03-09 2022-09-15 Alexander Mark Schobel Dosage forms having equivalent biocomparable profiles
AU2022416279A1 (en) 2021-12-15 2024-07-25 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
AU2023207214A1 (en) * 2022-01-14 2024-08-29 Center For Excellence In Molecular Cell Science , Chinese Academy Of Sciences Cyclopiperidine compound, preparation method therefor, and use thereof
CN114456149A (zh) * 2022-02-24 2022-05-10 中国科学技术大学 一种多巴胺drd2受体拮抗剂及其用途
WO2023178111A2 (en) * 2022-03-14 2023-09-21 Intra-Cellular Therapies, Inc. Organic compounds
CA3245613A1 (en) * 2022-03-14 2023-09-21 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
IL316924A (en) 2022-05-18 2025-01-01 Intra Cellular Therapies Inc Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
CN119930620A (zh) * 2024-02-05 2025-05-06 和径医药科技（上海）有限公司 四并环类化合物、其制备方法、药物组合物及应用
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299078A (en) * 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3892746A (en) 1969-06-09 1975-07-01 American Home Prod Pyrrolo{8 1,2,3-de{9 quinoxalin-2(3H)-ones and related compounds
US3891643A (en) 1972-05-15 1975-06-24 American Home Prod Pyrrolo{8 1,2,3-de{9 quinoxalin-2-(3H)-ones and related compounds
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
JPS4949999A (no) * 1973-06-19 1974-05-15
FR2213283A1 (en) * 1973-11-15 1974-08-02 Inst Im Ordzhonikidze Pyrazino(1,2,3-ab)beta carbolines and homologues - antidepressants not acting by MAO inhibition
JPS569510B2 (no) * 1973-11-17 1981-03-02
US4088647A (en) 1976-02-04 1978-05-09 Glushkov Robert Georgievich Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same
US4219550A (en) * 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
ATE136032T1 (de) 1987-07-20 1996-04-15 Duphar Int Res 8,9-anellierte 1,2,3,4-tetrahydro-beta-carbolin- derivate
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
EP0347980A1 (en) * 1988-06-20 1989-12-27 Duphar International Research B.V 8,9-Annelated beta-carbolines and 8,9-anelated-3,4-dihydro-beta-carbolines
US4997831A (en) 1988-09-01 1991-03-05 Glaxo Group Limited Lactam derivatives
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
CA2011107A1 (en) 1990-02-28 1991-08-31 David E. Bays Lactam derivatives
US5512575A (en) 1991-08-15 1996-04-30 Zeneca Limited Methanoanthraceneyl methyl piperidinyl compounds
AU7949694A (en) 1993-10-20 1995-05-08 Tokyo Tanabe Company Limited Indole derivative
US5654139A (en) 1994-09-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Allelic variation of the serotonin 5HT2c receptor
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
AU764766B2 (en) 1998-04-14 2003-08-28 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
PE20010052A1 (es) * 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
AR024378A1 (es) * 1999-06-15 2002-10-02 Du Pont Pharm Co Gamma-carbolinas fusionadas heterociclicas sustituidas

Also Published As

Publication number Publication date
CN1371374A (zh) 2002-09-25
JP2003502330A (ja) 2003-01-21
MXPA01012914A (es) 2004-04-21
EP1189904A1 (en) 2002-03-27
US20060178362A1 (en) 2006-08-10
AU5737900A (en) 2001-01-02
NO20016116D0 (no) 2001-12-14
NO20016128L (no) 2002-02-11
US6548493B1 (en) 2003-04-15
US20040034015A1 (en) 2004-02-19
ES2223536T3 (es) 2005-03-01
CA2373920A1 (en) 2000-12-21
CN1370176A (zh) 2002-09-18
HK1042481A1 (zh) 2002-08-16
WO2000077002A1 (en) 2000-12-21
AR024378A1 (es) 2002-10-02
ATE277928T1 (de) 2004-10-15
NO20016128D0 (no) 2001-12-14
ES2223537T3 (es) 2005-03-01
DE60014370D1 (de) 2004-11-04
JP4762465B2 (ja) 2011-08-31
BR0012084A (pt) 2002-04-02
JP2003502331A (ja) 2003-01-21
HK1043112A1 (zh) 2002-09-06
DE60014083T2 (de) 2006-03-02
AR024379A1 (es) 2002-10-02
CN1370169A (zh) 2002-09-18
US6552017B1 (en) 2003-04-22
WO2000077001A1 (en) 2000-12-21
JP2003502336A (ja) 2003-01-21
ATE277048T1 (de) 2004-10-15
MXPA01012970A (es) 2003-10-14
US7238690B2 (en) 2007-07-03
CA2374239A1 (en) 2000-12-21
DE60014083D1 (de) 2004-10-28
NO20016115L (no) 2002-02-12
WO2000077010A2 (en) 2000-12-21
BR0012086A (pt) 2002-04-02
ES2228549T3 (es) 2005-04-16
WO2000077010A3 (en) 2001-06-28
AU5615900A (en) 2001-01-02
HK1042480A1 (zh) 2002-08-16
MXPA01012969A (es) 2003-10-14
US7081455B2 (en) 2006-07-25
BR0012411A (pt) 2002-04-16
US20040127482A1 (en) 2004-07-01
EP1189905A1 (en) 2002-03-27
IL147108A0 (en) 2002-08-14
EP1192165A2 (en) 2002-04-03
CA2381322A1 (en) 2000-12-21
DE60014079D1 (de) 2004-10-28
EP1192165B1 (en) 2004-09-22
ATE277055T1 (de) 2004-10-15
NO20016116L (no) 2002-02-11
IL147109A0 (en) 2002-08-14
EP1189905B1 (en) 2004-09-29
DE60014370T2 (de) 2006-02-09
AU5738000A (en) 2001-01-02
NZ516031A (en) 2003-10-31
JP4863591B2 (ja) 2012-01-25
US20040209864A1 (en) 2004-10-21
AR024377A1 (es) 2002-10-02
DE60014079T2 (de) 2006-03-02
USRE39680E1 (en) 2007-06-05
TR200103658T2 (tr) 2002-06-21
ZA200109735B (en) 2004-01-27
JP4916633B2 (ja) 2012-04-18
IL145998A0 (en) 2002-07-25
EP1189904B1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
NO20016115L (no) Substituerte heterosykelkondenserte gamma-karbolin
PT1224180E (pt) Azois substituidos
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE50007953D1 (de) Beleuchtungsanordung
DE50008613D1 (de) Sicherungsring
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003660D1 (de) Diacylhydrazinderivate
NO20022927D0 (no) Substituerte pyrrazoler
DE50003259D1 (de) Textilie
DE50006013D1 (de) Anschlagpuffer
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole
ATE440824T1 (de) Nitro-sulfobenzamide
DE50009208D1 (de) Hydroxyphenylvinylthiazole
DE50006829D1 (de) Benzoylpyridazine
DE10082008D2 (de) Ausbeulgerät

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application